These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 35843739)

  • 1. Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors.
    Starks DC; Rojas-Espaillat L; Meissner T; Williams CB
    Gynecol Oncol; 2022 Sep; 166(3):403-409. PubMed ID: 35843739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
    Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
    Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
    Coleman N; Stephen B; Fu S; Karp D; Subbiah V; Ahnert JR; Piha-Paul SA; Wright J; Fessahaye SN; Ouyang F; Yilmaz B; Meric-Bernstam F; Naing A
    Cancer Med; 2024 Feb; 13(3):e6877. PubMed ID: 38400671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study.
    Bellmunt J; Maroto P; Bonfill T; Vazquez F; Perez-Gracia JL; Juanpere N; Hernandez-Prat A; Hernandez-Llodra S; Rovira A; Juan O; Rodriguez-Vida A
    Clin Genitourin Cancer; 2024 May; 22(5):102123. PubMed ID: 38905731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.
    Han SN; Oza A; Colombo N; Oaknin A; Raspagliesi F; Wenham RM; Braicu EI; Jewell A; Makker V; Krell J; Alía EMG; Baurain JF; Su Z; Neuwirth R; Vincent S; Sedarati F; Faller DV; Scambia G
    Gynecol Oncol; 2023 Nov; 178():110-118. PubMed ID: 37839313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.
    Burris HA; Kurkjian CD; Hart L; Pant S; Murphy PB; Jones SF; Neuwirth R; Patel CG; Zohren F; Infante JR
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):261-273. PubMed ID: 28601972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
    Voss MH; Gordon MS; Mita M; Rini B; Makker V; Macarulla T; Smith DC; Cervantes A; Puzanov I; Pili R; Wang D; Jalal S; Pant S; Patel MR; Neuwirth RL; Enke A; Shou Y; Sedarati F; Faller DV; Burris HA
    Br J Cancer; 2020 Nov; 123(11):1590-1598. PubMed ID: 32913286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.
    Shimizu T; Kuboki Y; Lin CC; Yonemori K; Yanai T; Faller DV; Dobler L; Gupta N; Sedarati F; Kim KP
    Target Oncol; 2022 Jan; 17(1):15-24. PubMed ID: 34843044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.
    Choueiri TK; Porta C; Suárez C; Hainsworth J; Voog E; Duran I; Reeves J; Czaykowski P; Castellano D; Chen J; Sedarati F; Powles T
    Oncologist; 2022 Dec; 27(12):1048-1057. PubMed ID: 36146944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors.
    Gouda MA; Shunyakova J; Naing A; Dumbrava E; Hong DS; Yuan Y; Yang P; Myers A; Liang Y; Peng J; Karp D; Tsimberidou AM; Rodon J; Yap TA; Piha-Paul SA; Meric-Bernstam F; Fu S
    ESMO Open; 2024 Jun; 9(6):103486. PubMed ID: 38914452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
    Falchook G; Coleman RL; Roszak A; Behbakht K; Matulonis U; Ray-Coquard I; Sawrycki P; Duska LR; Tew W; Ghamande S; Lesoin A; Schwartz PE; Buscema J; Fabbro M; Lortholary A; Goff B; Kurzrock R; Martin LP; Gray HJ; Fu S; Sheldon-Waniga E; Lin HM; Venkatakrishnan K; Zhou X; Leonard EJ; Schilder RJ
    JAMA Oncol; 2019 Jan; 5(1):e183773. PubMed ID: 30347019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
    Rodrigues HV; Ke D; Lim J; Stephen B; Bellido J; Janku F; Zinner R; Tsimberidou A; Hong D; Piha-Paul S; Fu S; Naing A; Subbiah V; Karp D; Falchook G; Kurzrock R; Wheler J
    Invest New Drugs; 2015 Jun; 33(3):700-9. PubMed ID: 25902899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
    Coleman RL; Handley KF; Burger R; Molin GZD; Stagg R; Sood AK; Moore KN
    Gynecol Oncol; 2020 May; 157(2):386-391. PubMed ID: 32037195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.
    Hurvitz SA; Dalenc F; Campone M; O'Regan RM; Tjan-Heijnen VC; Gligorov J; Llombart A; Jhangiani H; Mirshahidi HR; Tan-Chiu E; Miao S; El-Hashimy M; Lincy J; Taran T; Soria JC; Sahmoud T; André F
    Breast Cancer Res Treat; 2013 Oct; 141(3):437-46. PubMed ID: 24101324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
    Wheler J; Mutch D; Lager J; Castell C; Liu L; Jiang J; Traynor AM
    Oncologist; 2017 Apr; 22(4):377-e37. PubMed ID: 28275119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
    Khawaja MR; Nick AM; Madhusudanannair V; Fu S; Hong D; McQuinn LM; Ng CS; Piha-Paul SA; Janku F; Subbiah V; Tsimberidou A; Karp D; Meric-Bernstam F; Lu KH; Naing A
    Cancer Chemother Pharmacol; 2016 May; 77(5):973-7. PubMed ID: 27014780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.
    Pishvaian MJ; Slack R; Koh EY; Beumer JH; Hartley ML; Cotarla I; Deeken J; He AR; Hwang J; Malik S; Firozvi K; Liu M; Elston B; Strychor S; Egorin MJ; Marshall JL
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):843-53. PubMed ID: 23014737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
    Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
    BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors.
    Colombo I; Genta S; Martorana F; Guidi M; Frattini M; Samartzis EP; Brandt S; Gaggetta S; Moser L; Pascale M; Terrot T; Sessa C; Stathis A
    Clin Cancer Res; 2021 Sep; 27(18):5012-5019. PubMed ID: 34266890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
    Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
    Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.